NasdaqHealth CarePharmaceutical PreparationsWEST VANCOUVER, British Columbia, Canada

BriaCell Therapeutics Corp. BCTX

Ask your AI

Estimated market cap $29.60M8.73M shares, shares as of Oct 28, 2026CIK 1610820

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

1.4% of shares · 0 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

What changed in BriaCell Therapeutics Corp.'s latest quarterly report, compared with the one before.

We have not read a recent 10-Q for this company yet.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No recent insider purchases or sales for this company.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

122,978 shares

11 funds report BCTX. Values checked against market prices.

Funds own 5.6% of shares (Q2 2026)

18 funds hold the stock.

Q3 2026: 1.4% · 5,560 of ~8,900 funds reported so far

Q3 20250.7%
Q4 20250.5%
Q1 20265.3%
Q2 20265.6%
Q3 2026 (so far)1.4%

Q3 2026. 1 new, 0 added to, 4 trimmed, 8 exited since Q2 2026.

Top 13F holders
#
1	Iridian Asset Management LLC 13F ↗	65,000	$278.2K	unchanged
2	HRT Financial LP 13F ↗	35,248	$150.0K	n/a
3	Jane Street Group, LLC 13F ↗	21,734	$93.0K	-18.0%
4	Morgan Stanley 13F ↗	420	$1,798	-59.3%
5	UBS Group AG 13F ↗	373	$1,596	-99.1%
6	Allworth Financial LP 13F ↗	100	$324	unchanged
7	SSA Swiss Advisors AG 13F ↗	37	$159	unchanged
8	Provenance Wealth Advisors, LLC 13F ↗	34	$146	New
9	Group One Trading LLC 13F ↗	16	$68	unchanged
10	Caitong International Asset Management Co., Ltd 13F ↗	10	$43	-70.6%

One of these funds reports its values in thousands of dollars; its figures are shown in dollars.

Download CSV Every fund that holds BCTX, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What BriaCell Therapeutics Corp. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What BriaCell Therapeutics Corp. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q3 2025	13	—	12,437	$136.5K
Q4 2025	13	0	9,696	$69.2K
Q1 2026	16	+3	386,814	$1.6M
Q2 2026	18	+2	486,391	$1.6M
Q3 2026	11	-7	122,978	$525.4K

Each point is a quarter-end, from Q3 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (107930307). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes1 in 12 mo 8-K eventsNone in 90 days Patents1 patent granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active IPO history5 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: BriaCell Therapeutics Corp.
Address: 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER, British Columbia, Canada V7T 2X1
Phone: (604) 921-1810
Fiscal year ends: Jul 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: British Columbia, Canada
Listed as: BCTX (Nasdaq), BCTXL (Nasdaq), BCTXZ (Nasdaq)
Former names: Ansell Capital Corp. (until 2014)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$3.39−$0.12 (−3.42%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $3.01 · High $3.95Nov 13, 2026

Aug 13, 2026Low $3.01 · High $4.32Nov 13, 2026

Nov 13, 2025Low $2.74 · High $12.64Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.